Endocrinology

Preventive Cardiology

Questions discussed in this category

For a patient with known CAD and low baseline HDL, would a PCSK9 inhibitor be a better option than a statin, given concerns for paradoxical lowering of HDL levels with statin therapy that we can encounter in the outpatient clinical setting?

4 Answers available

Would the diagnostic yield for ABIs or peripheral arterial duplex doppler in a patient with metal rods in both legs be similar or acceptable in comparison to those tests in a patient without metal rods?

1 Answer available

Would you consider adding niacin to the lipid lowering regimen in statin-intolerant patients who cannot afford PCSK9i or bempedoic acid?

Ferrell et al., PMID 38448791

6 Answers available

How do you counsel patients with metabolic syndrome who decline statin therapy and have low coronary calcium scores regarding their long term CVD risk?

1 Answer available

How should we approach the recommendation of intermittent fasting for weight loss in patients with pre-existing cardiovascular conditions, given the observed association of increased CV mortality with eating durations of less than 8 hrs?

Chen & Zhong, AHA/ASA Journals 2024

2 Answers available

Will TRYNGOLZA (olezarsen), recently approved for familial chylomicronemia syndrome, also lower triglycerides due to other genetic causes of hypertriglyceridemia?

2 Answers available

Is moderate-intensity statin plus ezetimibe just as effective as high-intensity statin monotherapy in preventing major cardiovascular events?

4 Answers available

Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?

Prattichizzo et al., PMID 39468384

1 Answer available

Would you recommend statin initiation in a young adult patient (age < 40) with type 1 diabetes mellitus and LDL cholesterol levels greater than 100 without any cardiovascular risk factors?

1 Answer available

Should we recommend SGLT2i initiation at discharge to all patients hospitalized with acute myocardial infarction?

Butler et al., PMID 38587237

1 Answer available

Does oral semaglutide provide similar cardiovascular risk reduction benefits as injectable semaglutide?

1 Answer available

Should low-intensity statins be favored to minimize the risk of diabetes onset while still offering cardiovascular benefit for patients with prediabetes where a statin is indicated?

Cholesterol Treatment Trialists' (CTT) Collaboration

2 Answers available

How do you counsel patients with non-statin associated inflammatory myopathies about statin use?

1 Answer available

Papers discussed in this category

Curr Rheumatol Rep, 2020 Aug 26

Lipid-lowering Therapies in Myositis.

The New England journal of medicine, 2024 Apr 06

Empagliflozin after Acute Myocardial Infarction.

The American journal of cardiology, 2004-02-01

Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).

Nature medicine, 2024 Feb 19

A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk.

Journal of clinical lipidology, 2024 Mar 29

A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice.

Journal of the American College of Cardiology, 1986-12

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.

The New England journal of medicine, 2011-12-15

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Current opinion in lipidology, 2007 Aug

Niacin in cardiovascular prevention: mechanisms, efficacy, and safety.

The American journal of cardiology, 2005 Jun 01

Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.

Trials, 2018 Mar 05

Improved adherence adjustment in the Coronary Drug Project.

The New England journal of medicine, 2014 Jul 17

Effects of extended-release niacin with laropiprant in high-risk patients.

JAMA, 1975 Jan 27

Clofibrate and niacin in coronary heart disease.

The New England journal of medicine, 2016 Sep 15

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

The New England journal of medicine, 2023 Nov 11

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

The New England journal of medicine, 2024 Apr 07

Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.

The New England journal of medicine, 2022 Apr 21

Calorie Restriction with or without Time-Restricted Eating in Weight Loss.

The lancet. Healthy longevity, 2024 Apr 05

Effects of 3 months of 10-h per-day time-restricted eating and 3 months of follow-up on bodyweight and cardiometabolic health in Danish individuals at high risk of type 2 diabetes: the RESET single-centre, parallel, superiority, open-label, randomised controlled trial.

Diabetes & metabolic syndrome, 2024 Feb 05

Does early time-restricted eating reduce body weight and preserve fat-free mass in adults? A systematic review and meta-analysis of randomized controlled trials.

Journal of clinical lipidology, 2022 Sep 11

Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association.

Endocrinology

Preventive Cardiology

Questions discussed in this category

Papers discussed in this category

Related Topics in Endocrinology